Author Details

Zhukova, L. G

Issue Section Title File
Vol 15, No 2S (2008) Articles Effektivnost' i bezopasnost' lapatiniba v kombinatsii s kapetsitabinom pri lechenii bol'nykh HER-2 pozitivnym metastaticheskim rakom molochnoy zhelezy
Vol 19, No 18 (2012) Articles Adjuvant therapy with trastuzumab for early-stage breast cancer: 12 or 24 months (based on ESMO data, Vienna, october, 2012)
Vol 20, No 8 (2013) Articles NOVYE VOZMOZhNOSTI TERAPII BOL'NYKh METASTATIChESKIM RAKOM MOLOChNOY ZhELEZY, POLUChAVShIKh RANEE ANTRATsIKLINI TAKSAN-SODERZhAShchUYu KhIMIOTERAPIYu: OBZOR LITERATURY I KLINIChESKIY SLUChAY
Vol 21, No 8 (2014) Articles DVOYNAYa BLOKADA HER2-PETsEPTOPA - NOVOE NAPRAVLENIE V LEChENII RAKA MOLOChNOY ZhELEZY S GIPEREKSPRESSIEY HER2
Vol 21, No 17 (2014) Articles Eribulin v lechenii metastaticheskogo raka molochnoy zhelezy s troynym negativnym fenotipom
Vol 21, No 17 (2014) Articles Pertuzumab - novyy vzglyad na HER2-polozhitel'nyy metastaticheskiy rak molochnoy zhelezy
Vol 23, No 8 (2016) Articles PLACE OF LAPATINIB IN THE THERAPY OF HER2-POSITIVE BREAST CANCER
Vol 23, No 8 (2016) Articles MODERN POSSIBILITIES OF MEDICAL TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BLADDER CANCER
Vol 23, No 8 (2016) Articles CLINICAL CASE OF SUCCESSFUL TREATMENT OF METASTATIC COLORECTAL CANCER WITH ACHIEVEMENT OF COMPLETE PATHOMORPHOLOGICAL RESPONSE (FIRST LINE CHEMOTHERAPY)
Vol 23, No 17 (2016) Articles FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
Vol 23, No 17 (2016) Articles RESOLUTION SUMMARIZING THE RESULTS OF THE EXPERT COUNCIL "MODERN APPROACHES TO THE TREATMENT OF HER2-NEGATIVE METASTATIC BREAST CANCER. PROSPECTS FOR THE USE OF ERIBULIN AS A PART OF COMBINATION THERAPY FOR BREAST CANCER"
Vol 24, No 8 (2017) Articles Ixempra - new possibilities of cytostatic therapy of breast cancer
Vol 24, No 17 (2017) Articles Palbociclib - new possibilities of therapy of hormon-positive HER2-negative breast cancer
Vol 28, No 7 (2021) Articles Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
Vol 28, No 7 (2021) Articles Olaparib -modern approach to the treatment of BRCA-associated HER2-negative metastatic breast cancer. Clinical experience